Business
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial results and provided a corporate update.
About this update from Talphera, Inc.
[{"type":"text","content":"Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million ","length":182,"tagName":"p","attribs":{}},{"type":"text","content":"Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET","length":76,"tagName":"p","attribs":{}},{"type":"text","content":"SAN MATEO, Calif., May 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial results and provided a corporate update.","length":338,"tagName":"p"},{"type":"text","content":""We remain on track with new study site activation, including three institutions already activated and beginning to screen patients in 2025, and five new potentially high-enrolling sites by mid-year. The new target profile of our clinical study sites has proven beneficial as engagement with the principal investigators and activity at the sites is much higher than with the legacy sites with which we first initiated the study," stated Vince Angotti, CEO of Talphera. "We believe that the increased engagement from the new sites, including those expected to come on board in the coming months, will allow us to complete the 70-patient study by the end of the year. We expect our next enrollment update to occur when we enroll 17 patients, which is the milestone for closing the second tranche of our recent financing. Our confidence in the need for this product candidate continues to grow as we introduce more physicians to the Niyad clinical profile and NEPHRO study," continued Angotti.","length":1010,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Recent Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In March 2025, the Company announced it received approval from the U.S. Food and Drug Administration (FDA), on its Prior Approval Supplement (PAS) requesting a reduction...